January might offer a new year reset, but chronic illness demands us to move forward and bring what we’ve learned, says ...

England's NICE is recommending natalizumab, sold as Tysabri and Tyruko, as an NHS-covered treatment option for people with ...

This study demonstrated progressive CP enlargement over time in individuals with RRMS, averaging 1.4% a year with significant variation per participant. CP enlargement correlated with the expansion of ...

Please provide your email address to receive an email when new articles are posted on . Individuals enrolled in the open-label extension experienced low discontinuation rates. Those who remained in ...

Medicare drug plans are increasingly excluding coverage of new specialty drugs that treat complex conditions like cancers and autoimmune diseases. New research from the USC Schaeffer Center shows how ...

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will impact their patients. Dr ...

NICE has recommended Tysabri and biosimilar Tyruko as an option for patients with highly active relapsing-remitting multiple sclerosis.

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis (MS), suggest phase II study findings showing its efficacy in controlling inflammatory activity ...

Good physical performance is associated with better cognition in people with relapsing-remitting MS, according to a recent study by the University of Eastern Finland. Good functional capacity was also ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

The pain experience in women with RRMS has significant practice implications for nursing. The findings from this study may assist nurses practicing in hospitals and other settings within the community ...